Deliver Your News to the World

TGen and Geisinger Health System Announce Strategic Partnership to Shape Future of Personalized Medicine


Obesity and diabetes focus of first study

PHOENIX, Ariz., and DANVILLE, Pa. - The Translational Genomics Research Institute (TGen) and Geisinger Health System today announced the signing of a strategic research agreement that provides for a focused look at the gaps in clinical medicine where biomedical research can make a difference.

One of the first projects will focus on the causes of obesity, diabetes and other metabolic conditions. Researchers plan to look at the possible genetic reasons why so many Americans are overweight, and why diet, exercise and, specifically, bariatric surgery may fail to significantly reduce excess weight in some patients.

TGen, a non-profit biomedical research institute based in Phoenix, will pair its genomic and proteomic research expertise with the clinical excellence and research expertise of Geisinger, a non-profit medical and insurance provider based in Danville, Pa.

Geisinger’s strength is its integrated healthcare delivery model, nontransitory population and advanced electronic health record (EHR) with nearly two decades of data. In addition to providing the clinical underpinnings for the study of obesity, the data within the EHR will provide researchers the evidence they need to make discoveries in future projects centered on cancer and other serious diseases.

“Merging Geisinger’s wealth of clinical information with our genomic and proteomic expertise should provide researchers a richer framework for exploring the genetic origins of disease, and hopefully lead to improved treatments and outcomes,” said Dr. Jeffrey Trent, Ph.D., TGen’s President and Research Director.

TGen emphasizes a translational research process intended to quickly turn laboratory discoveries into new drugs and other treatments that can benefit patients, a goal shared by Geisinger.

"Given our unique research structure and a patient population that overwhelmingly supports cutting-edge research, I am confident that this partnership will allow us to test and apply new clinical translation theories to patient care,” said Glenn D. Steele, Jr., M.D., Ph.D., Geisinger’s President and CEO. “I look forward to the results of this first study, as I am confident we can greatly improve the outcomes for individuals coping with obesity and its many associated complications.”

According to 2009 Census data, nearly one-third of the U.S. adult population is overweight and considered obese. The impact of obesity on one’s health is great, often leading to a shortened lifespan. A disease, obesity is not always caused by overeating or lack of exercise, and research has shown there is often an underlying genetic component leading to excess weight gain.

David Carey, Ph.D., Director of the Sigfried and Janet Weis Center for Research, located on the campus of the Geisinger Medical Center, agreed that the collaboration should advance patient care. “Identification of patients at risk for chronic metabolic diseases would provide enormous benefit to health care. Geisinger’s ability to obtain detailed, electronic health information in real time for a large, stable patient population will significantly accelerate this research effort.”

Johanna DiStefano, Ph.D., Director of TGen’s Diabetes, Cardiovascular & Metabolic Diseases Division, will lead TGen’s efforts to understand the genetic basis of obesity and liver disease. She said research strategies would capitalize on the synergistic strengths of a large multidisciplinary research program in obesity at Geisinger. “I am confident that the long-term results of this collaboration will yield improved diagnostic and therapeutic outcomes for countless individuals suffering from chronic metabolic diseases.”

TGen also plans to bring to bear its collaboration with the Partnership for Personalized Medicine (PPM), which includes TGen, Arizona State University’s Biodesign Institute and the Fred Hutchinson Cancer Research Center. The PPM’s mission is to improve medical outcomes and reduced costs through more effective diagnosis of disease risk, early stage, and matching patients to therapies.

“Working with Geisinger will provide yet another significant opportunity for the Partnership for Personalized Medicine to provide better evidence to meet the specific medical needs of individual patients,” said Lee Hartwell, Ph.D., a 2001 Nobel laureate and Executive Committee Chairman of PPM.

The research partnership between TGen and Geisinger will also address some of the nation’s other critical health challenges. Preliminary discussions covered such research areas as genetic variations that predispose individuals to disease, congestive heart failure, abdominal aortic aneurysms, and the potential side effects of prescription drugs.

About Geisinger Health System
Founded in 1915, Geisinger Health System is based in Danville, Pa., and is one of the nation’s largest integrated health services organizations. Serving more than 2 million residents throughout central and northeastern Pennsylvania, the physician-led organization is at the forefront of the nation’s rapidly emerging electronic health records movement. Geisinger is comprised of two medical center campuses, three hospitals, a 740-member group practice, a not-for-profit health insurance company and a research program dedicated to creating innovative new models for patient care, satisfaction and clinical outcomes. For more information, visit:

About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit:


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.